Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Zacks Investment Research upgraded shares of Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Rating) from a hold rating to a buy rating in a research note published on Monday morning, Zacks.com reports. The brokerage currently has $0.75 target price on the stock. According to Zacks, “Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing […]
Cystic Fibrosis Foundation to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program Expect topline data from cystic fibrosis Phase 2 expansion treatment arms evaluating. | March 29, 2022
Eloxx Pharmaceuticals (NASDAQ:ELOX) Price Target Cut to $3 00 by Analysts at B Riley etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Zacks Investment Research Upgrades Eloxx Pharmaceuticals (NASDAQ:ELOX) to Buy etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.